<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d3ad1ad7-1d50-420e-9e4e-ba9283325925"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold"> Methenamine Hippurate Tablets, USP </content>
   </title>
   <effectiveTime value="20240613"/>
   <setId root="759b3725-0934-4974-a3ac-59a20aee81c6"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="081468959" root="1.3.6.1.4.1.519.1"/>
            <name>Viona Pharmaceuticals Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="650199482" root="1.3.6.1.4.1.519.1"/>
                  <name>Zydus Lifesciences Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650173735" root="1.3.6.1.4.1.519.1"/>
                        <name>Zydus Pharmaceuticals Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-175" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-175" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="904fe15e-8a2e-415c-936d-21cd3a6a57df"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20240613"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72578-175" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Methenamine hippurate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methenamine hippurate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="g"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="M329791L57" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHENAMINE HIPPURATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J50OIX95QV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHENAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="SB8ZUX40TY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SACCHARIN SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-175-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250312"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA219661" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250312"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>WHITE TO OFF WHITE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE">
                              <originalText>MODIFIED CAPSULE SHAPE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="2"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">II;C</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="b0acd97c-cb2a-451c-acee-256dff6b89fe"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID2">To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID3">
               <id root="a4720782-f2d4-40bb-ba9f-066f485ef34c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph ID="ID4">Each white to off-white colored, modified capsule-shaped tablet contains 1 g methenamine hippurate, USP which is the hippuric acid salt of methenamine (hexamethylene tetramine). In addition, each tablet contains the following inactive ingredients: crospovidone, colloidal silicon dioxide, magnesium stearate, povidone and saccharin sodium.</paragraph>
                  <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID32">
               <id root="ebe90cfb-f6ae-4346-9d92-465c42044541"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>ACTIONS</title>
               <effectiveTime value="20240613"/>
               <component>
                  <section ID="ID35">
                     <id root="8322e2cf-98b3-43b0-bb7f-f11bacceb9f6"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph ID="ID39">Methenamine hippurate tablets has antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid, the other component, has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against <content styleCode="italics">E. coli, </content>enterococci and staphylococci. <content styleCode="italics">Enterobacter aerogenes </content>is generally resistant. The urine must be kept sufficiently acid for urea-splitting organisms such as <content styleCode="italics">Proteus </content>and <content styleCode="italics">Pseudomonas </content>to be inhibited.</paragraph>
                     </text>
                     <effectiveTime value="20240613"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="896b2487-89c8-4560-9e95-670a0493b35a"/>
                     <title>Human Pharmacology</title>
                     <text>
                        <paragraph ID="ID41">Within 1/2 hour after ingestion of a single 1 gram dose of methenamine hippurate, antibacterial activity is demonstrable in the urine. Urine has continuous antibacterial activity when methenamine hippurate is administered at the recommended dosage schedule of 1 gram twice daily. Over 90% of methenamine moiety is excreted in the urine within 24 hours after administration of a single 1 gram dose. Similarly, the hippurate moiety is rapidly absorbed and excreted, and it reaches the urine by both tubular secretion and glomerular filtration. This action may be important in older patients or in those with some degree of renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20240613"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID9">
               <id root="17f87558-4c4c-4c1c-aa0f-718023f6f416"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS</title>
               <text>
                  <paragraph ID="ID10">Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents.</paragraph>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID11">
               <id root="595b5194-cc41-40d0-bd2b-9f9a05339776"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID12">Methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. Methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID13">
               <id root="75c4a104-e894-42a1-826a-869d6836378f"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNING</title>
               <text>
                  <paragraph ID="ID14">Large doses of methenamine (8 grams daily for 3 weeks to 4 weeks) have caused bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID15">
               <id root="2be2a6b2-86cb-4683-8196-d9b042fa94ef"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph ID="ID16">Prescribing methenamine hippurate in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                  <list listType="ordered" ID="ID17">
                     <item>Care should be taken to maintain an acid pH of the urine, especially when treating infections due to urea-splitting organisms such as <content styleCode="italics">Proteus </content>and strains of <content styleCode="italics">Pseudomonas.</content>
                     </item>
                     <item>In a few instances in one study, the serum transaminase levels were slightly elevated during treatment but returned to normal while the patients were still taking methenamine hippurate. Because of this report, it is recommended that liver function studies be performed periodically on patients taking the drug, especially those with liver dysfunction.</item>
                     <item>Use in Pregnancy: In early pregnancy the safe use of methenamine hippurate is not established. In the last trimester, safety is suggested, but not definitely proved. No adverse effects on the fetus were seen in studies in pregnant rats and rabbits. Methenamine hippurate taken during pregnancy can interfere with laboratory tests of urine estriol (resulting in unmeasurably low values) when acid hydrolysis is used in the laboratory procedure. This interference is due to the presence in the urine of methenamine and/or formaldehyde. Enzymatic hydrolysis, in place of acid hydrolysis, will circumvent this problem.</item>
                  </list>
               </text>
               <effectiveTime value="20240613"/>
               <component>
                  <section ID="ID20">
                     <id root="ebed637b-0d5f-407d-9654-e18c82ffccca"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph ID="ID21">Clinical studies of methenamine hippurate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Methenamine hippurate tablets are contraindicated in patients with renal insufficiency and severe hepatic insufficiency (see <content styleCode="bold">
                              <linkHtml href="#ID11">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Information for Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>Patients should be counseled that antibacterial drugs including methenamine hippurate should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When methenamine hippurate tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by methenamine hippurate or other antibacterial drugs in the future.</paragraph>
                     </text>
                     <effectiveTime value="20240613"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID24">
               <id root="fe1d0691-34e0-43a5-b81b-a4b7a5b11805"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID25">Minor adverse reactions have been reported in less than 3.5% of patients treated. These reactions have included nausea, upset stomach, dysuria, and rash.</paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID26">
               <id root="469f2c96-198e-406f-9e43-5523c90889fd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID27">1 tablet (1 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 g to 1 g) twice daily (morning and night) for pediatric patients 6 years to 12 years of age. Since the antibacterial activity of methenamine hippurate tablets is greater in acid urine, restriction of alkalinizing foods and medications is desirable. If necessary, as indicated by urinary pH and clinical response, supplemental acidification of the urine should be instituted. The efficacy of therapy should be monitored by repeated urine cultures.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID28">
               <id root="89c8bc46-574b-46df-8ecc-629c2df51ce7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph ID="ID29">Methenamine hippurate tablets, USP are white to off-white colored, modified capsule-shaped, uncoated tablets, debossed with "II" and "C" on one side and score line on both the sides. </paragraph>
                  <paragraph>NDC 72578-175-01 in bottle of 100 tablets with child-resistant closure</paragraph>
                  <paragraph>Store at 20°C to 25°C (68ºF to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in well-closed, light-resistant container with child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID30">
               <id root="1d1c3c9e-2ae0-4415-858f-235c49e0a215"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID31">
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Pharmaceuticals Ltd.</content>
                  </paragraph>
                  <paragraph>Ahmedabad-382213, India</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Viona Pharmaceuticals lnc.</content>
                  </paragraph>
                  <paragraph>Cranford, NJ 07016</paragraph>
                  <paragraph>Rev.: 05/24</paragraph>
               </text>
               <effectiveTime value="20240613"/>
            </section>
         </component>
         <component>
            <section ID="ID36">
               <id root="2b22c0f0-f3be-4fec-95ba-46e9ea4269ed"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID37">NDC 72578-175-01</paragraph>
                  <paragraph>Methenamine Hippurate Tablets, USP 1gram</paragraph>
                  <paragraph>100 tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20240613"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>METHENAMINE 1 G</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="d3ad1ad7-1d50-420e-9e4e-ba9283325925-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>